Total Payments
$28,118
2024 Payments
$11,164
Companies
6
Transactions
21
Payment Breakdown by Category
Consulting$25,414 (90.4%)
Research$1,700 (6.0%)
Other$526.50 (1.9%)
Food & Beverage$478.13 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $25,414 | 13 | 90.4% |
| Unspecified | $1,700 | 2 | 6.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $526.50 | 1 | 1.9% |
| Food and Beverage | $478.13 | 5 | 1.7% |
Payments by Type
General
$26,418
19 transactions
Research
$1,700
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $9,410 | 4 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,290 | 5 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $6,458 | 5 | $0 (2024) |
| GENZYME CORPORATION | $3,683 | 5 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $1,238 | 1 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $40.10 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,164 | 10 | Regeneron Pharmaceuticals, Inc. ($5,018) |
| 2023 | $957.17 | 3 | GENZYME CORPORATION ($917.07) |
| 2022 | $1,440 | 1 | Regeneron Pharmaceuticals, Inc. ($1,440) |
| 2021 | $3,607 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($3,080) |
| 2020 | $1,540 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($1,540) |
| 2019 | $2,310 | 1 | Shire North American Group Inc ($2,310) |
| 2018 | $3,850 | 2 | Shire North American Group Inc ($3,850) |
| 2017 | $3,250 | 1 | Shire North American Group Inc ($3,250) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,370.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/08/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $948.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $144.96 | General |
| Category: Immunology | ||||||
| 11/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $1,276.88 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $422.78 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,094.00 | General |
| Category: Immunology | ||||||
| 03/07/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Consulting Fee | Cash or cash equivalent | $2,490.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/21/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Consulting Fee | Cash or cash equivalent | $1,237.50 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/07/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $40.10 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/23/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $113.07 | General |
| 03/09/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $804.00 | General |
| Category: Immunology | ||||||
| 12/16/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/21/2021 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $526.50 | General |
| 12/09/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,080.00 | General |
| 02/20/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $1,540.00 | General |
| 03/06/2019 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $2,310.00 | General |
| 12/04/2018 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $2,310.00 | General |
| 05/02/2018 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $1,540.00 | General |
| 07/06/2017 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS | Regeneron Pharmaceuticals, Inc. | $1,700 | 2 |
About Dr. Vincent Mukkada, MD
Dr. Vincent Mukkada, MD is a Pediatric Gastroenterology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316023021.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vincent Mukkada, MD has received a total of $28,118 in payments from pharmaceutical and medical device companies, with $11,164 received in 2024. These payments were reported across 21 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($25,414).
Ad
Practice Information
- Specialty Pediatric Gastroenterology
- Location Cincinnati, OH
- Active Since 10/27/2006
- Last Updated 02/01/2013
- Taxonomy Code 2080P0206X
- Entity Type Individual
- NPI Number 1316023021
Products in Payments
- DUPIXENT (Biological) $9,541
- EOHILIA (Drug) $2,670
- VOQUEZNA (Drug) $1,238
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Gastroenterology Doctors in Cincinnati
William Balistreri, M.d, M.D
Pediatric Gastroenterology — Payments: $142,484
Pediatric Gastroenterology $142,484
Ajay Kaul, M.d, M.D
Pediatric Gastroenterology — Payments: $54,840
Pediatric Gastroenterology $54,840
Dr. Akihiro Asai, M.d., Ph.d, M.D., PH.D
Pediatric Gastroenterology — Payments: $30,394
Pediatric Gastroenterology $30,394
Khalil El-Chammas, M.d, M.D
Pediatric Gastroenterology — Payments: $16,719
Pediatric Gastroenterology $16,719
Samuel Kocoshis, M.d, M.D
Pediatric Gastroenterology — Payments: $14,994
Pediatric Gastroenterology $14,994
Jose' Garza, M.d, M.D
Pediatric Gastroenterology — Payments: $14,003
Pediatric Gastroenterology $14,003